Ovarian cancer is one of the leading causes of death from cancer in females, worldwide. An early diagnosis of ovarian carcinoma is likely to improve clinical outcome of patients in terms of reduced morbidity and mortality. The objective of our project is the proteomic analysis of ovarian malignant and non-malignant tissue samples to find potential biomarkers of disease diagnosis and prognosis that can be assessed non-invasively through patient plasma/serum screening. In this project, we have used a methodical approach involving 2-dimensional gel electrophoresis in conjunction with MALDI-TOF MS analysis followed by immunological validation of the selected markers by western blotting and ELISA for identification of biomarkers of ovarian cancer. The associated research paper is in preparation.